Clinical Trial Update: A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating BL-B01D1 with a tyrosine kinase inhibitor, with or without pembrolizumab, in patients with locally advanced or metas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• BL-B01D1
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Renal Cancer | Phase 2 | Status: RECRUITING